.png){kind=icon}
-
Blog
-
The COVID-19 road to recovery: coordinating clinical trial testing and central lab solutions
Jul. 16, 2020 324.3Kb
-
Protecting the safety of pediatric clinical trial participants during a
pandemic
Jul. 16, 2020 90.0Kb
-
Building efficiencies into decentralized long-term follow-up studies
Jul. 13, 2020 155.4Kb
-
-
Latest Thinking
-
Protecting the safety of pediatric clinical trial participants during a
pandemic
Jul. 16, 2020 90.0Kb
-
The COVID-19 road to recovery: coordinating clinical trial testing and
central
lab solutions
Jul. 16, 2020 324.3Kb
-
Laboratory Inspection Support in China by Expanded Laboratory Management
Solutions Team Case Study
Jul. 15, 2020 78.2Kb
-
Services
Preclinical
Plan your next preclinical study or partner with us for an IND/CTA-enabling package to get you from research to clinical trials faster. Save up to 30% on your preclinical timeline.
Learn MoreExplore Our Categories
DISEASE MODELS
Oncology Models and Cell Lines
Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.
Read More
ADMINISTRATION ROUTE
Inhalation Testing Capabilities
Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.
Read More
PROGRAMMATIC DEVELOPMENT
IND/CTA-Enabling Packages
Accelerate your molecule’s success with Early Phase Development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.
Read More
MARKETPLACE
Find the Right Partner
Find the right partner with the desire and resources to help you realize your asset’s potential. Through our private, secure and exclusive online portal, you can share information about your asset to attract potential investors or partners. It's one more innovative way to transform your program.
Read MorePreclinical Facilities & Locations
Enjoy global support and capacity for your preclinical studies with labs strategically positioned around the world. View all facilities
Unleash the Power of Connected Insights
The landscape of development is becoming more complex. You still need your studies delivered on-time and on-budget.
By connecting inspiring science with data, our committed scientific teams uncover insights from preclinical and clinical studies to help you reach your development milestones.
By the Numbers
Preclinical supported
81%
of the FDA's 2019 NDA/BLA drugs
Preclinical supported
77%
of the FDA's 2019 biologics
Save up to
30%
on your preclinical timeline
More than
125
billion SEND data points submitted
Have Questions?
- Can I buy more than one study or capability at a time?
Yes! While you can purchase individual studies and tests, you can also choose from one of our early development packages to help you move more quickly to development.
- Where are you located? Will you have capacity for my work?
We are a global preclinical CRO with labs servicing the Americas, Europe and Asia.
- What regulatory expertise can you provide?
We work closely with regulatory agencies such as FDA, CFDA/NMPA, EU and PMDA as well as EPA, ECHA and OECD to help you reach regulatory compliance.
- Do you test for more than pharmaceutical products?
Yes! We also provide services for medical devices, crop protection and chemical testing.
- How can I contact Covance?
We'd love to learn more about your project! Complete this form to be contacted by a member of our research support team.
Testimonial
“A dependable and reliable source for complicated studies with dedicated and extremely competent study direction.” –Project leader from a global pharmaceutical company
Covance Insights
Treating age-related macular degeneration (AMD) with a novel stem cell therapy Article Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50. There are no promising treatment options to slow the progression of AMD, and at present there is no way to stop or reverse the disease course. The most common advanced type of AMD in United States is the dry form of the disease, affecting 80-90% individuals with AMD. There is no approved treatment or cure for dry AMD.... Read More 
A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments Blog 
MC38: An immunoresponsive murine tumor model Model Spotlight 
In vitro cytokine release assays: is there calm after the storm? Blog Visit the Knowledge Library to learn more about our industry.
Sign Up Now!